- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Mark Stejbach, Merck
S
Mark Stejbach
VP, Managed Care Marketing, Merck
DOUBLE DUTY: Is helping build Merck's new healthcare model
OF NOTE: First non-finance person to run Merck's investor relations
On payers:
For many years, the success of the industry was at least in part driven by the inefficiency of the economic model of healthcare. In the short term, there's always more to be eked out from the current model—and I think some companies are going to run with that as hard and as long as they can. But in the long term, companies have to understand that the market is going to be increasingly influenced by the people who pay the bills—payers and consumers. In that way, pharma will start to become more like most other industries.
Mark Stejbach
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
